A consecutive population-based series of 372 adult acute myeloid leukemias, successfully cytogenetically investigated at a single center between 1976 and 1993, is reported. All medical records were reviewed in order to ascertain the prognostic impact of karyotype, divided into three groups; favorable (t(8;21), t(15;17), and inv(16) irrespective of karyotypic complexity; n = 40), poor (der(1;7), inv(3), −5, del(5q), −7, t(9;22), and complex karyotypes including whole or partial losses of chromosomes 5 and/or 7; n = 56), and intermediate ( 
Introduction
During the last two decades, cytogenetic as well as molecular genetic investigations have increasingly become a part of the standard diagnostic and prognostic evaluation of malignant hematologic disorders. [1] [2] [3] [4] The prognostic implication of cytogenetic patterns in acute myeloid leukemia (AML) was already reported in the early 1970s. 5 Since then, several studies have demonstrated that AML-associated chromosomal abnormalities can be subgrouped into several categories with different prognostic effects. [6] [7] [8] [9] [10] In 1982, the Fourth International Workshop on Chromosomes in Leukemia showed, for the first time, that the karyotype is an independent prognostic factor in AML. 11 Certain abnormalities, such as t(8;21)(q22;q22) in AML-M2, t(15;17)(q22;q12-21) in AML-M3, and inv(16)(p13q22) in AML-M4Eo, are now known to confer a better prognosis, 10, [12] [13] [14] whereas other changes, for example der(1;7)(q10;p10), inv(3)(q21q26), and whole or partial losses of chromosomes 5 and 7, are strongly associated with a dismal outcome. 9, 10, 15 Although these reported clinicogenetic associations most likely are correct, several previous studies focusing on the prognostic impact of cytogenetic abnormalities in AML have been hampered by either small numbers of patients or by including selected patients evaluated and treated at several different centers. Furthermore, often all age groups have been considered together, not taking into account the possibility of age-related differences. We have ascertained the prognostic impact of karyotype, and whether this impact is modified by age, gender, time period, and morphology, in a population-based consecutive series of 372 adult patients with AML, for which the cytogenetic investigations have been carried out at the same center.
Materials and methods

Patients
The study is based on a consecutive series of 1500 adult patients with suspected or confirmed hematologic malignancy, successfully cytogenetically analyzed at the Department of Clinical Genetics, Lund University Hospital, Sweden, between 1976 and 1993. The basic demographic, morphologic, and cytogenetic data on this cohort have been reported previously. 16 The medical records and bone marrow findings of the 372 AML, de novo (n = 318) as well as secondary (n = 54), patients (median age 63 years), constituting the present study group, were reviewed. The diagnoses are based on the morphologic findings present at the time of karyotypic investigation. [17] [18] [19] [20] [21] Due to the long study period (18 years), the chemotherapeutic regimens have varied, but have at any given time been comparable among the referring hospitals. In general, patients below the age of 65-70 have been treated with a curative intent with standard AML protocols including an anthracycline and cytarabine. Initial treatment decisions were not influenced by the cytogenetic findings. Since 1981, bone marrow transplantation (BMT), autologous as well as allogeneic, has been available as an option, and 32 of the patients treated since then have been transplanted. Survival was calculated from the date of diagnosis to the date of death or date of last follow-up (1 June 1998).
Cytogenetic investigations
All cytogenetic investigations have, since 1976, been performed on bone marrow and/or peripheral blood samples in a standardized fashion. In short, the cells were adjusted to a concentration of 10 6 /ml and cultured for 24 and 48 h in McCoy's 5A medium supplemented with fetal calf serum, Lglutamine and antibiotics, and the chromosome preparations were made in a standard manner and banded by trypsinGiemsa technique. The definition and description of clonal abnormalities have, throughout the study period, followed the recommendations of 'An International System for Human Cytogenetic Nomenclature', the most recent being ISCN (1995). 22 In general, 25 metaphases were analyzed. The cytogenetic investigation was considered a failure if less than 10 metaphases could be investigated, unless a cytogenetically abnormal clone was identified.
For the present study, the karyotypic patterns of all cases were subdivided into three groups: (1) 'favorable' prognosis, ie t(8;21), t(15;17), and inv(16) irrespective of karyotypic complexity (n = 40; 11%); (2) 'poor' prognosis, ie der(1;7), inv(3), −5, del(5q), −7, t(9;22), and complex karyotypes, ie у3 aberrations, including whole or partial losses of chromosomes 5 and/or 7 (n = 56; 15%); and (3) 'intermediate' prognosis, ie other abnormalities or normal karyotype (n = 276; 74%).
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Statistics
Cox regression was employed to estimate the effect of karyotype, ie favorable, intermediate or poor prognosis abnormalities, on survival time. All patients were included in the analyses, whether they achieved remission or not. For comparisons of the categories, the hazard ratios (HR) with 95% confidence intervals (CI) were estimated. In multivariate Cox regression models, we also considered age at diagnosis (four categories: 20-49, 50-64, 65-74 and у75 years), calendar year (two categories: 1976-1987 and 1988-1993; chosen to get near equal numbers in each category), gender, morphologic subtype (five categories: M1/M2, M3, M4/M5, other FAB types, and unspecified), and BMT. In particular, modification of the effect of karyotype by each of those additional factors was tested. 23 Kaplan-Meier curves for survival data were visually assessed to ensure that the proportional hazard assumption was reasonable and to depict any modifications by relevant factors on the cytogenetic prognostic groups.
Results
Descriptive data on the 372 AML patients are given in Table  1 . The effect of karyotype on survival, in a univariate analysis, is depicted in Figure 1 . With the favorable prognosis group as the reference, the intermediate and the poor prognosis groups showed increased hazard ratios (HR 2.1, 95% CI 1.4-3.1, P Ͻ 0.001, and HR 4.2, 95% CI 2.6-6.7, P Ͻ 0.001, respectively). There was no evidence that the prognostic impact of the cytogenetic patterns was significantly modified by gender, morphology, or BMT (data not shown). In contrast the HR varied with time period (P = 0.05) and age (P = 0.03) ( Table 2 ). The survival curves for the first and second time periods and for the different age groups (except у75 years due to low number of cases) are shown in Figures 2a, b and 3a-c, respectively.
Discussion
The aim of the present study was to evaluate the prognostic impact of acquired cytogenetic abnormalities in a consecutive series of 372 adult AML. Age, gender, morphology and time period were included in the analyses, in order to ascertain whether the impact was modified by these factors. Further subgrouping of the patients would not have yielded meaningful statistical results and was hence not performed. Selection bias is a major problem in investigations of this kind, but we strongly believe that such a bias has been minimized in the present series. In favor of this conclusion is the relatively high median age (63 years), which exceeds what has been reported in previous studies addressing the prognostic impact of karyotype in AML. 6, 9, 10, 12, [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] It should be stressed, however, that some AML in our region have not been cytogenetically characterized. This group, the size of which may be close to 50%, 37 consists mainly of elderly patients, too frail for curative as well as palliative chemotherapy.
The salient features of the present study were that the relative association between cytogenetic patterns and survival was not modified by gender or morphology, whereas age and time period significantly influenced this association. The number of patients was too small to allow investigation of the modifying impact of both these factors together. A few AML studies, incorporating karyotypic data, have shown that women may have a better prognosis. 25, 38 However, most other investigations have not shown such an association, 7, 26, 28, 31, 39 and these studies, as well as the present results, suggest that even if a minor gender-related survival difference in relation to cytogenetic patterns were to exist in AML, the effect would presumably be of no clinical importance. Also the prognostic impact of morphology, ie FAB subtype, has received much attention. Several investigations addressing this question have reported significant differences in univariate analyses, but when multivariate models have been used, taking into account other factors, such as age, gender, karyotype, white blood cell and platelet counts, Auer rods, bone marrow cellularity, degree of dysplasia, and percentage of myeloblasts, it has become evident that the FAB subtype is not an independent prognostic factor. 7, 25, 26, 28, 31, 34, [39] [40] [41] Thus, our finding that morphologic subgroup did not significantly modify the survival curves for the different cytogenetic prognostic groups agrees well with the results of these previous investigations.
Leukemia
Age is generally considered to be the most important prognostic factor in AML, 12, [26] [27] [28] [29] 31, 34, 40, 42, 43 although this has been disputed. 44 The strong impact of age on survival was apparent also in the present study (Figure 3 ). It should be noted, however, that the oldest age group (у75 years) was too small to be investigated in detail in this regard. Thus, the influence of advanced age on prognosis remains to be clarified. In the three other age groups (20-49, 50-64, and 65-74), the intermediate and poor prognosis abnormality groups did worse with increasing age, whereas the favorable prognosis group continued to do relatively well. In fact, a longer median survival in this prognosis group was noted for patients 50-64 years of age, and even longer for the age group 65-74 years. Interestingly, there were no clear-cut differences among the survival curves for the three prognostic groups at ages 20-49 (Figure 3a) . Whether this is an effect of BMT, other therapeutic interventions, or factors unrelated to treatment is presently unclear.
The comparison between cases diagnosed 1976-1987 and 1988-1993 revealed that the poor prognosis group continued to do poorly, that the intermediate group showed a slight improvement in survival, whereas the favorable prognosis group seems to do better in the later time period (Figure 2 ). To the best of our knowledge, no previous studies focusing on calendrical differences in outcome in relation to karyotypic prognostic groups in AML have been reported. Although further studies are needed on this subject, our results strongly suggest that the improvement in survival prospect seen during the last decade for AML patients is mainly confined to the favorable and intermediate prognosis groups. In contrast, the outcome for the unfavorable karyotypic subgroup was remarkably, and disappointingly, similar in the two time periods (Figure 2) . Thus, new and innovative treatment strategies are badly needed for this patient group.
